FILE:LH/LH-8K-20060517114121.txt.gz
EVENTS:	Regulation FD Disclosure
TEXT:
ITEM: Regulation FD Disclosure
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
ITEM 7.01. Regulation FD Disclosure
Summary information of the Company dated May 17, 2006.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Thomas P. Mac Mahon Chairman and Chief Executive Officer Annual Meeting May 17, 2006
 
            
This slide presentation contains forward-looking statements which are subject to change based on various important factors, including without limitation, competitive actions in the marketplace and adverse actions of governmental and other third-party payors.  Actual results could differ materially from those suggested by these forward-looking statements. Further information on potential factors that could affect the Company's financial results is included in the Company's Form 10-K for the year ended December 31, 2005, and subsequent filings.
2
 
The Clinical Laboratory Testing Market - $40 billion Annually
Independent clinical lab share is $16 billion
Represents 2% to 3% of all health care spending
Influences /directs approximately 80% of health care spending
Rapidly evolving technology, emphasis on preventative medicine and aging of population are all driving growth
Has grown at a CAGR of between 5% and 6%
Source:    Company estimates, industry reports and 2005 revenue for LabCorp.
3
 
Profile of LabCorp
A leader in the esoteric and genomic testing market and second-largest clinical laboratory company in North America
Offers a broad range of routine and esoteric/genomic tests
Conducts approximately 1.1 million tests daily on more than 360,000 specimens
Provides lab services to physicians and other health care providers
Approximately 24,000 employees nationwide
4
 
Primary Testing Locations
Primary LabCorp Testing Locations
Corporate Headquarters
Burlington, NC
5
 
LabCorp's Strategy
            
To
lead
the industry in achieving long- term
growth and profitability
by strengthening our
nationwide core testing
business and expanding our
higher-growth, higher-value esoteric and genomic businesses
.
6
 
Strategic Focus Areas
Scientific
Leadership
Managed
Care
Customer
Retention
-Licensing/partnerships
-Cancer
-Specimen tracking
-Call center consolidation
-Report improvement
-Acquisitions
-Appropriate prices
-Reduce leakage
-Value of new lab tests
-Customer connectivity
7
 
LabCorp's Investment and Performance Fundamentals
History of Strong Financial Performance
Significant Cash Generator
Industry leading EBITDA margins
Strong Balance Sheet
Investment Grade Credit Ratings
8
 
2005 Achievements
Expanded our national strategic partnership with Wellpoint  Georgia, Nevada
1st national laboratory to offer Cytyc's ThinPrep Imaging System
Completed acquisitions of US LABS and Esoterix
Operating cash flow of $574.2 million
Repurchased approximately $588.5 million of LabCorp stock
9
 
2006 Achievements To Date
Diluted EPS of $0.78
(1)
EBITDA margin of 26.1% of sales
Increased revenues 9.9% (4.6% volume; 5.3% price)
Operating cash flow of $178.6 million
Repurchased $185.1 million of LabCorp stock
(1)  Excluding the $0.02 per diluted share impact of the required change in accounting for stock based compensation.
10
 
Five-Year Revenue and EPS Trend
Revenue CAGR of 11%   -   Diluted EPS CAGR of 22%
(1)
(1) Excluding the $0.09 per diluted share impact in 2005 of restructuring and other special charges, and a non-recurring investment loss.
11
 
LabCorp Common Stock Performance
Stock Price On Annual Meeting Date
(1) Closing price on May 16, 2006
(1)
12
 
Reconciliation of Non-GAAP Financial Measures
($ in millions)
13
 


